Trialssemaglutidebariatric surgeryobesityclinicaltrials.gov

Egyptian trial to test immediate semaglutide after weak bariatric surgery response

The phase 4 randomized, double-blind strategy trial pits treatment at the 12-month plateau against the current practice of waiting for established failure.

By Priya Raman · Science Reporter

Oct 5 08:00 ETSource: ClinicalTrials.gov

The wire

01NCT07859189, sponsored by Egypt's General Committee of Teaching Hospitals and Institutes, is not yet recruiting, with a start listed for October 2026, in morbid obesity after metabolic and bariatric surgery.
02It tests timing rather than efficacy: BARI-STEP already showed 18.0% loss versus 0.4% gain at 68 weeks with semaglutide 2.4 mg in 70 post-surgical patients a mean of seven years out.
03The 2024 IFSO consensus on withholding drugs until plateau rests on expert agreement, not trial data; this registration is a protocol only, with no enrollment or results yet.

From the source

Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery
NCT07859189 · PHASE4 · NOT YET RECRUITING · Sponsor: General Committee of Teaching Hospitals and Institutes, Egypt · Conditions: Morbid Obesity.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT07859189